Review: adverse effects of different second-generation antipsychotics vary in children and adolescents

2012 ◽  
Vol 15 (4) ◽  
pp. 100-100 ◽  
Keyword(s):  
Adverse Effects ◽  
Children And Adolescents ◽  
Second Generation ◽  
Second Generation Antipsychotics

Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents

2012 ◽  
Vol 32 (3) ◽  
pp. 309-316 ◽  
Author(s):  
David Cohen ◽  
Olivier Bonnot ◽  
Nicolas Bodeau ◽  
Angèle Consoli ◽  
Claudine Laurent
Keyword(s):  
Adverse Effects ◽  
Children And Adolescents ◽  
Second Generation ◽  
Second Generation Antipsychotics

The use of second generation antipsychotics in children and adolescents with bipolar disorder and schizophrenia: A summary of the AHRQ comparative effectiveness review

2013 ◽  
Vol 2 (11) ◽  
pp. 350-352
Author(s):  
Jeani Pulsipher ◽  
Gary M. Levin
Keyword(s):  
Bipolar Disorder ◽  
Adverse Effects ◽  
Children And Adolescents ◽  
Mood Disorders ◽  
Comparative Effectiveness ◽  
Second Generation ◽  
Pediatric Patients ◽  
Healthcare Research ◽  
Second Generation Antipsychotics

Second generation antipsychotics (SGAs) can be effective in treating mood disorders in pediatric patients; however, these medications also present with a risk of serious adverse effects. A recent review by the Agency for Healthcare Research and Quality (AHRQ) evaluated the use of SGAs in pediatric patients. This article summarizes the findings of the review, with a focus on bipolar disorder and schizophrenia.

Poster #S2 CARDIOMETABOLIC ADVERSE EFFECTS OF SECOND-GENERATION ANTIPSYCHOTICS IN DRUG NAÏVE CHILDREN AND ADOLESCENTS IN ACUTE CARE

2014 ◽  
Vol 153 ◽  
pp. S88
Author(s):  
Marco Armando ◽  
Luigi Mazzone ◽  
Valeria Lucarelli ◽  
Valentina Postorino ◽  
Maria Laura Pucciarini ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Children And Adolescents ◽  
Acute Care ◽  
Second Generation ◽  
Second Generation Antipsychotics ◽  
Drug Naïve

Metabolic and Cardiac Side Effects of Second-generation Antipsychotics: What Every Clinician Should Know

2009 ◽  
Vol 22 (5) ◽  
pp. 478-488 ◽  
Author(s):  
Ericka L. Breden ◽  
Mei T. Liu ◽  
Stacey R. Dean ◽  
Toyin S. Tofade
Keyword(s):  
Cardiovascular Disease ◽  
Health Care ◽  
Adverse Effects ◽  
Second Generation ◽  
Antipsychotic Agents ◽  
The United States ◽  
Natural Death ◽  
Cardiac Side Effects ◽  
Second Generation Antipsychotics ◽  
Physical Health Care

In 2007, 5 of the 7 second-generation antipsychotics were listed in the Top 200 Drugs prescribed by retail sales in the United States. Cardiovascular disease is the leading cause of natural death in individuals with schizophrenia. Second-generation antipsychotics have been implicated with metabolic and cardiovascular adverse effects, and it is important for nonpsychiatric practitioners to be familiar with the monitoring parameters recommended for these agents. This article discusses the risk of weight gain, hyperglycemia, hyperlipidemia, hyperprolactinemia, and cardiovascular concerns associated with second-generation antipsychotic agents. It also discusses the proposed mechanisms for each of these adverse effects. Furthermore, it reviews suggested monitoring parameters to help manage cardiovascular disease in this patient population, and to improve the gap that exists between mental health care and physical health care in the schizophrenic population.

Sign in / Sign up

Export Citation Format

Share Document